Nucleolar organizer regions (NORs) on cytological imprints of breast cancers. A comparative study with ploidy, Ki-67 immunostaining, morphological classifications and hormone receptors

1992 ◽  
Vol 76 (1) ◽  
pp. 268
Author(s):  
WOZNIAK
2000 ◽  
Vol 20 (4) ◽  
pp. 155-162 ◽  
Author(s):  
Lukas Günther ◽  
Peter Hufnagl ◽  
Klaus‐Jürgen Winzer ◽  
Hans Guski

The relation between estrogen receptors (ER) and argyrophilic nucleolar organizer regions (AgNORs)in situwithin human breast cancer cells was analyzed. For AgNOR measurements in 49 invasive breast carcinomas, a new reproducible staining method for dual demonstration of ER and AgNORs was applied. Quantitative AgNOR variables were determined in ER‐positive and ER‐negative tumor cells by digital image analysis. The relationships between AgNOR parameters of ER‐positive and ER‐negative cells and other prognostic factors of breast cancer [Bloom–Richardson‐Grading and growth fraction (Ki‐67 index)] were investigated. A higher AgNOR content in ER‐negative cells and a special clustering phenomenon in ER‐positive tumor cells were found. Correlation with other criteria of malignant potential could be exclusively demonstrated for ER‐negative cells. ER‐negative cells of breast cancer can be characterized as the more malignant and possibly prognosis‐dictating cell fraction. Thus, ER‐negative cells probably contribute more to the progression of the tumor disease and furthermore to the prognosis than ER‐positive cells. We recommend measurement AgNORs exclusively in ER‐negative cells of breast cancer.


1997 ◽  
Vol 34 (2) ◽  
pp. 138-145 ◽  
Author(s):  
G. Minkus ◽  
U. Jütting ◽  
M. Aubele ◽  
K. Rodenacker ◽  
P. Gais ◽  
...  

Canine pancreatic neuroendocrine tumors were studied using different image analysis techniques (nuclear image histometry, analysis of argyrophilic proteins of nucleolar organizer regions, determination of the mouse anti-Ki 67 antigen proliferation index, and DNA densitometry) to correlate their biological behavior with objective phenotypic markers. The methods were compared to determine the best method for distinguishing between metastatic and nonmetastatic tumors. Discrimination between the two types of tumor was possible using nuclear image histometry in combination with morphometric analysis of argyrophilic proteins of nucleolar organizer regions. In contrast, the mouse anti-Ki 67 antigen proliferation index, DNA measurement, and immunohistochemical parameters revealed no significant difference between the two types of tumors.


2017 ◽  
Vol 22 (3) ◽  
pp. 153-157
Author(s):  
Artak U. Panasyan ◽  
D. S Kobyakov ◽  
A. M Avdalyan ◽  
A. A Ivanov ◽  
E. L Lushnikova ◽  
...  

Study of markers of apoptosis and proliferation in relation to clinical and morphological parameters in non-small cell cancer (NSCLC) patients and healthy persons. There were investigated 237 surgery samples of NSCLC and 10 cases of normal lung tissues. p53, bcl-2, bax, Ki-67, topoisomerase IIα (ТороIIα) levels were determined by immunohistochemical method. Argyrophilic proteins associated with nucleolar organizer regions (AgNOR) were detected with silver nitrate. In NSCLC expression of p53, bcl-2, Ki-67, TopoIIα, AgNOR increased and expression of bax was lower if compared with the normal tissue. Expression of apoptotic markers (p53, bcl-2, bax) correlated with clinical and morphological parameters of NSCLC: histogenesis, N index and the stage (for bcl-2), gender (for bax). Expression of Ki-67 and TopoIIα correlated with gender, largest size of the tumor, histogenesis and differentiation. AgNOR proteins were interrelated with the gender, T and N indices, largest tumor dimension, stage, histogenesis and differentiation. In NSCLC cases the expression of apoptotic markers correlated with proliferation: in p53 positive tumors - high level of proliferation (Ki-67, TopoIIα, AgNOR), in bcl-2 positive tumors - low AgNOR, in bax positive tumors - low proliferative activity (Ki-67, TopoIIα). In NSCLC there is observed the change in expression of apoptotic markers (p53, bcl-2, bax) and proliferation (Ki-67, TopoIIα, AgNOR) in conjunction with normal tissue and clinical and morphological parameters of tumor.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 623-623
Author(s):  
Giovanna Masci ◽  
Michele Caruso ◽  
Agnese Losurdo ◽  
Piermario Salvini ◽  
Carlo Carnaghi ◽  
...  

623 Background: The overall incidence of male breast cancers (MBC) is around 1% of all breast cancers and is on the rise.Most of our current knowledge regarding its biology and treatment strategies has been extrapolated from its female counterpart. However, from literature data, it is more and more evident that MBC has biological differences compared with female breast cancer (FBC). While hormone receptors are more frequently positive in MBC than in FBC, HER-2 seems to be less expressed in MBC than in FBC, with data ranging from 0 to 18%; no data on Ki-67 have been so far reported. Methods: We retrospectively analyzed the immunohistochemical expression of hormone receptors status, HER-2 protein expression, and Ki-67 in 76 consecutive MBCs, treated within the Humanitas Institutes Network on Cancer Research (INCaRe). HER-2 determinations were carried out according to ASCO/ACP and NEQAS guidelines: cases with score 2+ at IHC were further examined by fluorescent in situ hybridation (FISH). Results: From 2000 to 2011, we treated 76 male breast cases (age 25-87, median 64): 72 patients (94%) had ductal carcinoma and 4 had rare histotypes (2 papillary, 1 mucinous and 1 cribryform). Thirthy-two of 76 patients (42%) had positive axillary lymph-nodes, while 6 (8%) were metastatic at diagnosis. Of these, estrogen receptor and progesterone receptor were positive in 96% and 93% patients respectively; HER-2, evaluable in 67 patients, was positive in 11 (16%). Ki-67 was evaluable in 75 patients and was > 20% in 24 cases (32%), with 20/24 (26%) with Ki-67 > 30%. Grading was evaluable in 65 patients: G1 in 2 (3%), G2 in 41(63%) and G3 in 22 (34%), respectively. Conclusions: In these series, MBC show different patterns from FBC, with some favorable aspects such as higher hormone receptor status and much lower HER-2 expression and some unfavorable features, such as higher Ki-67 values. Although further studies are needed to confirm these data, different treatment strategies would be suggested in MBC than its female counterpart.


BIOCELL ◽  
2005 ◽  
Vol 29 (1) ◽  
pp. 33-38
Author(s):  
CARLOS A. MART蚇 ◽  
JOS�MIGUEL SURUR ◽  
MARCELA N. GARC虯 ◽  
F蒐IX CORRONS ◽  
AMADO F. BADR罭

Sign in / Sign up

Export Citation Format

Share Document